Showing results (211-220 of 225) with videos related to
Sort By:
Pageof 23
The New England Journal of Medicine|August 21, 2024
Belzutifan versus Everolimus for Advanced Renal-Cell CarcinomaToni K Choueiri, Thomas Powles, Katriina Peltola, et al.European Journal of Cancer (Oxford, England : 1990)|August 6, 2021
Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trialOrazio Caffo, Cinzia Ortega, Franco Nolè, et al.Journal of Translational Medicine|August 30, 2019
Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final resultsGaetano Facchini, Sabrina Rossetti, Massimiliano Berretta, et al.Cancer Immunology, Immunotherapy : CII|February 3, 2026
Effectiveness of ICI-ICI versus ICI-TKI combinations in patients with IMDC intermediate- and poor-risk metastatic renal cell carcinoma: a sub-analysis of the MEET-URO 33 studyMichele Maffezzoli, Alessio Signori, Alessandro Acunzo, et al.Cancer Immunology, Immunotherapy : CII|May 29, 2023
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 studyMatteo Santoni, Zin W Myint, Thomas Büttner, et al.Therapeutic Advances in Medical Oncology|May 28, 2021
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)Sara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna, et al.Cancers|January 8, 2020
Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic FactorsMatteo Santoni, Daniel Y Heng, Sergio Bracarda, et al.Clinical Genitourinary Cancer|April 16, 2023
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)Matteo Santoni, Francesco Massari, Zin W Myint, et al.Targeted Oncology|June 27, 2023
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 StudyMatteo Santoni, Francesco Massari, Zin W Myint, et al.Nature Medicine|June 25, 2026
Metabolic determinants of cancer immunotherapy outcomes identified by plasma profilingDéborah Suissa, Marine Fidelle, Ella Reich, et al.Pageof 23